Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 169


In situ tumor ablation creates an antigen source for the generation of antitumor immunity.

den Brok MH, Sutmuller RP, van der Voort R, Bennink EJ, Figdor CG, Ruers TJ, Adema GJ.

Cancer Res. 2004 Jun 1;64(11):4024-9.


Synergistic antitumor effect of chemotactic-prostate tumor-associated antigen gene-modified tumor cell vaccine and anti-CTLA-4 mAb in murine tumor model.

Li N, Qin H, Li X, Zhou C, Wang D, Ma W, Lin C, Zhang Y, Wang S, Zhang S.

Immunol Lett. 2007 Nov 15;113(2):90-8. Epub 2007 Aug 29.


Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor.

Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM.

J Immunol. 2005 Jun 15;174(12):7516-23.


Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity.

den Brok MH, Sutmuller RP, Nierkens S, Bennink EJ, Frielink C, Toonen LW, Boerman OC, Figdor CG, Ruers TJ, Adema GJ.

Br J Cancer. 2006 Oct 9;95(7):896-905. Epub 2006 Sep 5.


Melanoma-infiltrating dendritic cells induce protective antitumor responses mediated by T cells.

Preynat-Seauve O, Contassot E, Schuler P, French LE, Huard B.

Melanoma Res. 2007 Jun;17(3):169-76.


Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.

Choi KJ, Kim JH, Lee YS, Kim J, Suh BS, Kim H, Cho S, Sohn JH, Kim GE, Yun CO.

Gene Ther. 2006 Jul;13(13):1010-20. Epub 2006 Mar 9.


Tumor cell loaded type-1 polarized dendritic cells induce Th1-mediated tumor immunity.

Hokey DA, Larregina AT, Erdos G, Watkins SC, Falo LD Jr.

Cancer Res. 2005 Nov 1;65(21):10059-67.


Augmentation of antitumor immune responses after adoptive transfer of bone marrow derived from donors immunized with tumor lysate-pulsed dendritic cells.

Asavaroengchai W, Kotera Y, Koike N, Pilon-Thomas S, Mulé JJ.

Biol Blood Marrow Transplant. 2004 Aug;10(8):524-33.


Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb.

Li B, Lin J, Vanroey M, Jure-Kunkel M, Jooss K.

Clin Immunol. 2007 Oct;125(1):76-87. Epub 2007 Aug 13.


Cross-reactive antigen is required to prevent erosion of established T cell memory and tumor immunity: a heterologous bacterial model of attrition.

Smith DK, Dudani R, Pedras-Vasconcelos JA, Chapdelaine Y, van Faassen H, Sad S.

J Immunol. 2002 Aug 1;169(3):1197-206.


Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo.

Sanchez-Perez L, Kottke T, Diaz RM, Ahmed A, Thompson J, Chong H, Melcher A, Holmen S, Daniels G, Vile RG.

Cancer Res. 2005 Mar 1;65(5):2009-17.


Complete regression of advanced primary and metastatic mouse melanomas following combination chemoimmunotherapy.

Kohlmeyer J, Cron M, Landsberg J, Bald T, Renn M, Mikus S, Bondong S, Wikasari D, Gaffal E, Hartmann G, Tüting T.

Cancer Res. 2009 Aug 1;69(15):6265-74. doi: 10.1158/0008-5472.CAN-09-0579. Epub 2009 Jul 21.


Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity.

Ramirez-Montagut T, Chow A, Hirschhorn-Cymerman D, Terwey TH, Kochman AA, Lu S, Miles RC, Sakaguchi S, Houghton AN, van den Brink MR.

J Immunol. 2006 Jun 1;176(11):6434-42.


Combined dendritic cell cryotherapy of tumor induces systemic antimetastatic immunity.

Machlenkin A, Goldberger O, Tirosh B, Paz A, Volovitz I, Bar-Haim E, Lee SH, Vadai E, Tzehoval E, Eisenbach L.

Clin Cancer Res. 2005 Jul 1;11(13):4955-61.


Inefficient presentation of tumor-derived antigen by tumor-infiltrating dendritic cells.

Stoitzner P, Green LK, Jung JY, Price KM, Atarea H, Kivell B, Ronchese F.

Cancer Immunol Immunother. 2008 Nov;57(11):1665-73. doi: 10.1007/s00262-008-0487-4. Epub 2008 Mar 1.


Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma.

Kline J, Brown IE, Zha YY, Blank C, Strickler J, Wouters H, Zhang L, Gajewski TF.

Clin Cancer Res. 2008 May 15;14(10):3156-67. doi: 10.1158/1078-0432.CCR-07-4696.

Supplemental Content

Support Center